CorrectionSchmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, and Scholz A (2013). Allosteric MEK1/2inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models ofhepatocellular carcinoma. Neoplasia 15, 1161–1171.

The correct pagination is 1147–1157.